Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
Type
[
Year
]
Filters:
Author
is
Liberati, Anna Marina
[Clear All Filters]
2024
Stathis A
,
Pirosa MCristina
,
Orsucci L
,
Feugier P
,
Tani M
,
Ghesquières H
,
Musuraca G
,
Rossi FGaia
,
Merli F
,
Guieze R
, et al.
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
Haematologica. 2024.
PubMed
Google Scholar
2023
Duell J
,
Abrisqueta P
,
André M
,
Gaidano G
,
Gonzales-Barca E
,
Jurczak W
,
Kalakonda N
,
Liberati AMarina
,
Maddocks KJ
,
Menne T
, et al.
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase II L-MIND study.
Haematologica. 2023.
PubMed
Google Scholar
2022
Schjesvold FH
,
Dimopoulos M-A
,
Delimpasi S
,
Robak P
,
Coriu D
,
Legiec W
,
Pour L
,
Spicka I
,
Masszi T
,
Doronin V
, et al.
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Lancet Haematol. 2022.
PubMed
Google Scholar
2021
Ferreri AJM
,
Doorduijn JK
,
Re A
,
Cabras MGiuseppina
,
Smith J
,
Ilariucci F
,
Luppi M
,
Calimeri T
,
Cattaneo C
,
Khwaja J
, et al.
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial.
Lancet Haematol. 2021;8(2):e110-e121.
PubMed
Google Scholar
2020
Santoro A
,
Mazza R
,
Pulsoni A
,
Re A
,
Bonfichi M
,
Zilioli VRuggero
,
Zanni M
,
Merli F
,
Anastasia A
,
Luminari S
, et al.
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma.
Blood Adv. 2020;4(1):136-140.
PubMed
Google Scholar
Salles G
,
Duell J
,
Barca EGonzález
,
Tournilhac O
,
Jurczak W
,
Liberati AMarina
,
Nagy Z
,
Obr A
,
Gaidano G
,
André M
, et al.
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Lancet Oncol. 2020.
PubMed
Google Scholar
2016
Santoro A
,
Mazza R
,
Pulsoni A
,
Re A
,
Bonfichi M
,
Zilioli VRuggero
,
Salvi F
,
Merli F
,
Anastasia A
,
Luminari S
, et al.
Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
J Clin Oncol. 2016.
PubMed
Google Scholar